DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...

Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

The Nifty Pharma index closed on a note on Wednesday. Shares of Dr. Reddy's Laboratories Ltd.(up 1.43 per cent) ended the day ...

Dr. Reddy's Laboratories Ltd. 500124 shares rallied 1.47% to 1,370.60 Indian rupees Wednesday, on what proved to be an ...

Dr Reddy's Laboratories Limited has announced the sale of its step-down wholly owned subsidiary, Dr Reddy's Laboratories ...

The S&P BSE Sensex was down 141.64 points to 78,057.47 at 10:09 am, while the NSE Nifty50 was trading 42.60 points lower at ...

Foreign institutional investors (FIIs) remained net sellers, offloading equities worth Rs 1,491.46 crore on January 7, while ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.